Clinical Trial Update: Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer [EARLY_Phase 1]

View source ↗

Summary

This early-phase 1 trial compares a non-fucosylated anti-CTLA-4 antibody (BMS-986218) plus degarelix acetate versus degarelix acetate alone in men with high-ris…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• BMS-986218 (non-fucosylated anti-CTLA-4 antibody)
• Degarelix Acetate (degarelix acetate)

Snippet

Sponsor: Columbia University | Conditions: Prostate Cancer | EARLY_Phase 1 | Status: COMPLETED